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DObjective: The Heart Rhythm Society, European Heart RhythmAssociation, and European Cardiac Arrhythmia
Society jointly recommend indefinite warfarin anticoagulation in patients with CHADS2 (congestive heart fail-
ure, hypertension, age, diabetes, and stroke) score of at least 2 who have undergone ablation for atrial fibrillation.
This study determined the impact of CHADS2 score on risk of late stroke or transient ischemic attack after the
performance of a surgical Cox maze procedure.
Methods:A retrospective review of 433 patientswho underwent aCoxmaze procedure at our institutionwas con-
ducted. Three months after surgery, warfarin was discontinued regardless of CHADS2 score if the patient showed
no evidence of atrial fibrillation, was off antiarrhythmic medications, and had no other indication for anticoagu-
lation.A follow-up questionnairewas used to determinewhether any neurologic event had occurred since surgery.
Results: Follow-up was obtained for 90% of the study group (389/433) at a mean of 6.6  5.0 years. Among
these patients, 32% (125/389) had a CHADS2 score of at least 2, of whom only 40% (51/125) remained on long-
term warfarin after surgery. Six patients had late neurologic events (annualized risk of 0.2%). Neither CHADS2
score nor warfarin anticoagulation was significantly associated with the occurrence of late neurologic events.
Among the individual CHADS2 criteria, both diabetes mellitus and previous stroke or transient ischemic attack
were predictive of late neurologic events.
Conclusions: The risk of stroke or transient ischemic attack in patients after a surgical Cox maze procedure was
low and not associated with CHADS2 score or warfarin use. Given the known risks of warfarin, we recommend
discontinuation of anticoagulation 3 months after the procedure if the patient has no evidence of atrial fibrilla-
tion, has discontinued antiarrhythmic medications, and is without any other indication for systemic anticoagu-
lation. (J Thorac Cardiovasc Surg 2013;146:85-9)Earn CME credits at
http://cme.ctsnetjournals.org
Atrial fibrillation (AF) is a common cardiac arrhythmia that
currently affects more than 2 million adults in the United
States and is projected to increase in prevalence approxi-
mately 2.5-fold by the year 2050.1 The most feared conse-
quence of AF is the increased risk of thromboembolic
complications, particularly stroke.2 The annualized risk of
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The Journal of Thoracic and Cand colleagues3 according to the CHADS2 score, a multifac-
eted index that is based on the presence of congestive heart
failure, hypertension, age of at least 75 years, diabetes melli-
tus, and stroke or transient ischemic attack (TIA) history. To
mitigate the risk of thromboembolic disease, current Heart
Rhythm Society (HRS), European Heart Rhythm Associa-
tion (EHRA), and European Cardiac Arrhythmia Society
(ECAS) joint guidelines recommend lifetime warfarin anti-
coagulation to an international normalized ratio of 2.0 to
3.0 for all patientswithAFand aCHADS2 score of at least 2.
4
Although controversial, the restoration of normal sinus
rhythm remains a goal by many clinicians in the treatment
of their patients with AF. Because of the limited efficacy
of antiarrhythmic drugs, both catheter-based and surgical
procedures have been introduced to treat AF.5,6 The Cox
maze procedure (CMP) is the criterion standard for the
surgical treatment of AF, offering more than 90%
freedom from AF5 and an annualized risk of late stroke of
less than 1% in several series.6-8 The efficacy of the CMP
for decreasing stroke risk has been attributed to both its
success at restoring sinus rhythm and the amputation or
exclusion of the left atrial appendage (LAA).9
The HRS, EHRA, and ECAS have cooperatively estab-
lished guidelines regarding the use or discontinuation ofardiovascular Surgery c Volume 146, Number 1 85
Abbreviations and Acronyms
AF ¼ atrial fibrillation
CMP ¼ Cox maze procedure
ECAS ¼ European Cardiac Arrhythmia Society
EHRA ¼ European Heart Rhythm Association
HRS ¼ Heart Rhythm Society
LAA ¼ left atrial appendage
TIA ¼ transient ischemic attack
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Dwarfarin in patients undergoing catheter-based procedures
for AF.4 Their consensus statement recommends that (1)
decisions regarding the use of warfarin for more than 2
months after ablation should be based on the patient’s risk
factors for stroke and not on the presence or type of AF
and (2) discontinuation of warfarin therapy after ablation
generally not be advised at any point for patients who
have a CHADS2 score of at least 2.
Because of the important differences that exist between
catheter-based and surgical techniques, it is unclear whether
patients undergoing the CMP should be treated according to
the same algorithm. The purpose of this study was to exam-
ine the impacts of the CHADS2 score and warfarin therapy
on the risk of stroke and TIA in patients who have under-
gone a CMP.MATERIALS AND METHODS
Surgical Management
Between September 1987 andMarch 2008, a total of 450 patients under-
went the CMP for AF at our institution as either a stand-alone procedure
(n ¼ 226) or concomitantly with other cardiac surgery (n ¼ 224). The
CMP has undergone several modifications since its inception. Patients un-
derwent either the CMP I (n¼ 33), CMP II (n¼ 16), CMP III (n¼ 197), or
the most recent iteration, the CMP IV (n ¼ 204) (5). All versions of the
CMP included amputation or exclusion of the LAA.
Postoperatively, all patients were anticoagulated with warfarin for 3
months unless contraindicated. After 3 months, warfarin therapy was dis-
continued for patients who were off all antiarrhythmic drugs and in normal
sinus rhythm, as determined by electrocardiography (1987-2002) or
24-hour Holter monitoring (2002-2008). Patients who did not meet these
criteria were instructed to continue warfarin anticoagulation. Warfarin
was also continued for patients with mechanical valves, left atrial stasis,
or thrombus as shown by the postoperative echocardiogram. Left atrial sta-
sis was defined as either the absence of an A wave or the presence of
‘‘smoke’’ within the left atrium. Longitudinal follow-up with evaluation
of rhythm was subsequently completed at 3 months, 6 months, 12 months,
and annually thereafter. This algorithm was followed without regard to the
patient’s CHADS2 score.
Long-Term Follow-up
A follow-up questionnaire and telephone script were composed and ap-
proved by the institutional review board, and all patients gave oral or writ-
ten consent before follow-up. This questionnaire asked whether the patient
had had a late stroke or TIA (defined as later than 90 days postoperatively)
and whether the patient was on a warfarin regimen at the time of follow-up.
Stroke and TIA were each defined as loss of neurologic function that was
abrupt in onset and lasted longer or shorter than 24 hours, respectively.86 The Journal of Thoracic and Cardiovascular SurgeFollow-up was performed for all cases in which at least 90 days had
elapsed from the date of surgery (n ¼ 433). Follow-up was completed by
patient interview (n ¼ 372) or by review of the most recent clinical record
when the patient could not be contacted (n¼ 17). All neurologic events re-
ported by patients were confirmed by acquiring medical records from the
physicians who had treated the patient at the time of the event. Records in-
cluded documentation of the patient’s anticoagulation and rhythm status.
Assignment of CHADS2 Scores
A computerized, prospective database was retrospectively queried to
determine the preoperative CHADS2 score for all patients.
3
Statistical Analysis
Continuous variables are expressed as mean  SD unless otherwise
specified. Categorical data are expressed as counts and proportions. Com-
parisons were performed with paired, 2-tailed t tests for means of normally
distributed continuous variables and with Wilcoxon rank sum tests for
skewed data. Either c2 or Fisher exact tests were used to compare categoric
data. Univariate binary logistic regression was used to determine predictors
of late neurologic complications. All data analyses were done with SPSS
statistical software (SPSS 11.0 for Windows; IBM Corporation, Armonk,
NY). Annual risk in this study was calculated as events per patient in the
subgroup divided by the mean follow-up within the subgroup.
RESULTS
Follow-up
Seventeen patients died within 90 days of the procedure
and were excluded. Of the 433 patients remaining, follow-
up was achieved for 90% (n ¼ 389), with a mean duration
of 6.6  5.0 years. These patients were subsequently di-
vided into high (2) and low (<2) CHADS2 score groups.
The follow-up was similarly complete for patients in both
the low CHADS2 score (91%; 264/291) and high CHADS2
score (88%; 125/142) groups (P ¼ .38).
Patient Demographic Characteristics
The patients in the high CHADS2 score group were older
and had a significantly higher prevalence of congestive
heart failure, hypertension, diabetes mellitus, and stroke
or TIA history than did those in the low CHADS2 score
group (Table 1). Furthermore, patients in the high CHADS2
score group were more likely to have had persistent AF and
larger left atria, despite a shorter preoperative duration of
AF. Finally, other concomitant cardiac surgery was more
commonly performed for patients in the high CHADS2
score group.
Neurologic Events
There were 6 neurologic events (stroke, n ¼ 4; TIA,
n ¼ 2) during the 21-year study period (2400 patient-
years), for an overall neurologic event risk of 0.2% per
year. The time to occurrence of a neurologic event ranged
from 0.3 to 12.5 years, with a mean of 4.8  4.6 years.
No neurologic events were hemorrhagic in nature, as docu-
mented by computed tomographic scanning.
The clinical details of each case are shown in Table 2. Of
the 6 neurologic events, half occurred in the low CHADS2ry c July 2013
TABLE 1. Patient characteristics stratified by CHADS2 score
CHADS2<2
(n ¼ 264)
CHADS2 2
(n ¼ 125)
P
value
Preoperative variables
Congestive heart failure 32 (12%) 80 (64%) <.001
Hypertension 73 (28%) 94 (75%) <.001
Age (y, mean  SD) 54  11 64  11 <.001
Diabetes mellitus 5 (2%) 24 (19%) <.001
Stroke or TIA history 0 57 (46%) <.001
AF variables
Paroxysmal AF 167 (64%) 57 (46%) <.001
Median AF duration
(y, IQR)
5.0 (2.5-10) 2.9 (0.8-7) .04
Mean left atrial diameter*
(cm, mean  SD)
5.0  1.3 5.4  1.3 .03
Procedural variables
Concomitant surgery 101 (38%) 91 (73%) <.001
Follow-up (y)
Mean  SD 7.5  5.1 4.6  4.2 <.001
Median and IQR 7.1 (2.4-11.8) 3.0 (1.3-6.5) <.001
Data are numbers and percentages of patients unless otherwise stated. AF, Atrial fi-
brillation; IQR, interquartile range; TIA, transient ischemic attack; SD, standard
deviation. *Variable available since February 2002 for 172 patients.
TABLE 3. Univariate analysis for the occurrence of a late neurological
event
Variables
Event free
(n ¼ 383)
Late TIA or
stroke (n ¼ 6)
P
value
CHADS2 variables
Congestive heart failure 111 (29%) 1 (17%) .68
Hypertension 163 (43%) 4 (67%) .41
Age 75 y 28 (7%) 0 >.999
Diabetes mellitus 27 (7%) 2 (33%) .07
Stroke or TIA history 54 (14%) 3 (50%) .04
CHADS2 score 2 122 (32%) 3 (50%) .39
Warfarin use at follow-up 121 (32%) 3 (50%) .39
Follow-up (y)
Mean  SD 6.6  5.0 7.9  6.4 .59
Median and interquartile range 5.5 (2.0-10.6) 9.1 (1.0-13.7) .68
Data are numbers and percentages of patients unless otherwise stated. TIA, Transient
ischemic attack; SD, standard deviation.
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undergone concomitant cardiac surgical procedures. Two
thirds of the events (4/6) occurred while the patient was
in normal sinus rhythm, and a third (2/6) occurred while
therapeutically anticoagulated with warfarin. Of note,
case 6 is a patient, who despite a therapeutic international
normalized ratio, had an intracardiac thrombus associated
with his prosthetic mitral valve and was subsequently diag-
nosed with a hypercoagulable disorder (antiphospholipid
antibody syndrome).Impact of Warfarin and CHADS2 on Risk of Late
Neurologic Events
Univariate analysis (Table 3) and univariate binary logis-
tic regression (Table 4) showed no association between ei-
ther a CHADS2 score 2 or warfarin use and theTABLE 2. Clinical data for neurologic events
Case Event Procedures
CHADS2
score Warfarin Rhythm
Time to
event (y)
1 TIA CMP III, CABG 0 No AF 12.5
2 TIA CMP IV, CABG 0 No NSR 1.3
3 Stroke CMP III 1 No NSR 0.8
4 Stroke CMP II 4 No NSR 1.8
5 Stroke CMP III 3 Yes NSR 11.8
6 Stroke CMP IV, MVR 5 Yes Atrial
flutter
0.3
AF, Atrial fibrillation; CABG, coronary artery bypass grafting; CMP, Cox maze pro-
cedure;MVR, mitral valve replacement; NSR, normal sinus rhythm; TIA, transient is-
chemic attack.
The Journal of Thoracic and Cdevelopment of a late stroke or TIA. Univariate analysis
identified previous stroke or TIA as the only variable to
be significantly more common (P ¼ .04) in the group
with late neurologic events. Logistic regression analysis
demonstrated that diabetes mellitus (odds ratio, 6.6;
P ¼ .03) and previous stroke or TIA (odds ratio, 2.5;
P¼ .03) were associated with increased risks of late neuro-
logical event. No association was found between the re-
maining CHADS2 criteria (congestive heart failure,
hypertension, age 75 years) and the development of late
stroke or TIA. The annualized risks of a neurologic event,
stratified by both CHADS2 score and warfarin use, are illus-
trated in Table 5. The event rate was low (0.9%) in all
groups.DISCUSSION
Neurologic Outcomes After a Cox Maze Procedure
A notable strength of this study is its size and complete-
ness of long-term follow-up. The follow-up in this study
was more extensive than previously performed for any
CMP population8 and exceeds what has been documentedTABLE 4. Univariate binary logistic regression with a dependent
outcome of late stroke or transient ischemic attack
Variables Odds ratio 95% CI P value
CHADS2 variables
Congestive heart failure 0.5 0.06-4.2 .52
Hypertension 2.7 0.49-14.9 .26
Age* 1.0 0.96-1.1 .39
Diabetes 6.6 1.2-37.6 .03
Stroke or TIA history 2.5 1.1-5.6 .03
CHADS 2 2.1 0.43-10.8 .36
Warfarin 2.2 0.43-10.9 .35
CI, Confidence interval; TIA, transient ischemic attack. *In this analysis, age was
treated as a continuous variable for the calculation of an odds ratio because no patients
aged 75 years or older had a late stroke or TIA.
ardiovascular Surgery c Volume 146, Number 1 87
TABLE 5. Risk of neurologic event by warfarin status and CHADS2
score
CHADS2<2 CHADS2 2 P value*
Off warfarin >.999
Patients 191 74
Events 3 1
Follow-up (y, mean  SD) 7.6  5.1 4.9  4.4
Annual risk 0.2% 0.3%
On warfarin .17
Patients 73 51
Events 0 2
Follow-up 7.4  5.3 4.2  3.7
Annual risk 0% 0.9%
P valuey .56 .57
SD, Standard deviation. *Comparison of stroke off warfarin between the low and high
CHADS2 score groups. yComparison of stroke in all patients between on and off war-
farin statuses.
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Dfor catheter-based and other percutaneous stroke-reduction
procedures.10-13
The overall annual risk of late stroke or TIA for patients
who underwent the CMP was 0.2%. The striking rarity of
these events after a CMP is not isolated to our particular se-
ries and has been similarly reported by other investigators in
separate CMP cohorts.8 The low risk of postoperative neu-
rologic events among patients who underwent a CMP is ac-
tually more similar to that of the general population14 than
to patients with untreated AF. For example, patients not re-
ceiving warfarin had an annual stroke risk less than 1%, re-
gardless of CHADS2 score group. This rate compares
favorably with the corresponding stroke rates per 100
patient-years of 2.8 and 4.0 to 5.9 per 100 patient-years
that would be predicted by Gage and colleagues3 for these
same patients without warfarin. This disparity is thought
to be related both to the high rate of restoration of sinus
rhythm after the CMP15,16 and to the fact that amputation
of the LAA is likely a critical mechanism of stroke
prevention. Numerous studies have shown that the LAA is
an important source of potential emboli.9,17 Moreover, the
latest iteration of the CMP (the CMP IV), as well as
previous iterations of the CMP, have been shown to
achieve drug-free freedom from AF of at least 84% of pa-
tients at 2 years postoperatively.18Impact of Warfarin and CHADS2 Score on Risk of
Late Neurologic Events
Therewas no association between CHADS2 score or war-
farin status and the development of late neurologic events in
this series. Although the composite CHADS2 score itself
did not have predictive value in this series, 2 of its individual
components (diabetes mellitus and stroke or TIA history)
were significantly associated with an increased risk of late
neurologic events. This is perhaps not surprising because
both diabetes and a history of stroke have been found to88 The Journal of Thoracic and Cardiovascular Surgebe highly predictive of stroke in several studies among
a wide range of populations, with or without the presence
of AF.14,19,20
Although warfarin anticoagulation was not associated
with a decrease in the incidence of late neurological events
in this series (odds ratio, 2.2; P ¼ .35), it is possible that
warfarin may have some undetected protective effect
against the future development of neurologic events. The
low incidence of events in this surgical series precludes
the demonstration of any significant association during
a mean follow-up period of 7 years. It is likely that the es-
tablishment of any incremental benefit of warfarin in
CMP patients will require a larger cohort size and longer
follow-up duration, approaching the scale of the warfarin
trials in the nonsurgical literature.21,22 However, it may be
justified to forego warfarin use after successful CMP
given the low postoperative embolic risk, and because any
undetected benefit of warfarin would be outstripped by
the 0.58% to 4.2% annual risk of major bleeding
associated with long-term anticoagulation.21-23
Applicability of the HRS, EHRA, and ECAS
Guidelines for Cox Maze
The HRS, EHRA, and ECAS have jointly developed
guidelines for the management of anticoagulation in pa-
tients who have undergone catheter-based ablation for AF.
These guidelines place a strong emphasis on the preopera-
tive CHADS2 score, to the extent that patients with
a CHADS2 score of at least 2 are not to be offered the dis-
continuation of warfarin therapy regardless of the outcome
of the procedure. Although these guidelines may be appro-
priate for catheter-based procedures, the relevance of these
guidelines to surgical patients undergoing a CMP is un-
known and cannot be assumed.
In this study, when patients met our defined criteria,
warfarin therapy was discontinued, regardless of preoper-
ative CHADS2 score. The incidence of late neurologic
events in this series was extremely low (0.2% annually),
and there was no association with either CHADS2 score
or warfarin use. On the basis of these findings, we discon-
tinue warfarin 3 months after the CMP if there is no evi-
dence of AF on prolonged monitoring, the patient is off all
antiarrhythmic drugs, and there is no other indication for
anticoagulation.
Study Limitations
Although the follow-up in this study was 90%, it was
limited by our inability to contact some patients. It is also
possible that some neurologic events were missed because
of their omission from patient reporting. A few studies,
however, have suggested that self-reporting is reliable,
even among elderly individuals, and may actually overesti-
mate the incidence of stroke.24,25 Furthermore, mean
follow-up was significantly shorter in the high CHADS2ry c July 2013
Pet et al Acquired Cardiovascular Disease
A
C
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toward offering surgical therapy to patients at higher risk
with proportionately higher CHADS2 scores. This inconsis-
tency notwithstanding, our mean follow-up of 4.6 years in
the high CHADS2 score group should be sufficient given
the high risk of predicted stroke in this group.
The inclusion of patients who underwent concomitant
surgery at the time of their CMP increases the heterogeneity
of our study group; however, this study group is a good ap-
proximation of patients undergoing a CMP in the current
era. Most centers perform the CMP in the setting of con-
comitant cardiac surgery. Studying this mixed population
is thus important in developing practice guidelines that
are applicable to the current practice environment.
The neurologic event rate was very low in all groups. Al-
though this low incidence during the course of 2400 patient-
years speaks well for the overall efficacy of the CMP, the
low number of events limits the inferences that can be
made from statistical comparisons between groups and re-
stricts our ability to perform multivariate logistic regres-
sion. As a consequence, the most important finding in this
study is the low overall incidence of stroke or TIA in this
population. The statistical significances of individual clini-
cal predictors of stroke or TIA are instructive but are cer-
tainly not conclusive evidence.
CONCLUSIONS
It seems prudent to develop anticoagulation guidelines
specifically for patients who have undergone surgical abla-
tion of AF with exclusion of the LAA. The presented find-
ings warrant consideration with respect to the management
of anticoagulation. Although further validation of these re-
sults will be required, our data suggest that anticoagulation
may be discontinued in patients who have undergone
a CMP, regardless of their preoperative CHADS2 scores.
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